Lilly is supportive of the European Parliament taking steps to address Alzheimer's disease (AD), a condition affecting 7 million EU citizens, by integrating it into the EU’s broader health strategies. This initiative aims to help healthcare systems overcome barriers to early and accurate diagnosis, ensure accessible care, and overcome ongoing stigma that those with AD face.

A diagnosis of Alzheimer’s disease (AD) can be devastating, both for the individual and their family. While AD impacts each person differently, one thing that all patients can benefit from is having more time to understand what changes lie ahead, and plan for their future. At Lilly, we recognize that access to early and accurate diagnosis is essential to connecting patients and their families to the care and support they need.

There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to transform timely, accurate diagnosis for the benefit of patients and healthcare systems.